Note 11 - Business Segment Reporting

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

11. Business Segment Reporting

The Company manages its operations as

one

segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. All Brazil sales are through

one

independent distributor, which is the only customer greater than

10%

of sales. The Company’s revenues by geographic region are as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Consolidated Revenue:
United States	$	7,102	$	7,535	$	20,969	$	22,392
Brazil		2,619		3,383		7,620		10,011
Other		131		98		374		335
Total Revenue	$	9,852	$	11,016	$	28,963	$	32,738